http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1558266-A4

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_22d9c3e7181797e9ffc06d95771a22f5
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
filingDate 2003-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5fb3c34e82cd2fe7e2cf84c0053895a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_923e16c38cadfc95d6a926af916ddcc7
publicationDate 2007-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-1558266-A4
titleOfInvention TREATMENT OF REACTIVE ARTHRITIS OR BURSITIS
abstract A pharmaceutical formulation for treating conditions in human beings associated with either or both reactive arthritis or bursitis comprising a combination of acyclovir, minocycline, hydrochloride, and metronidazole. An alternate treatment comprises the combination of valacyclovir hydrochloride , minocycline hydrochloride, and metronidazole.
priorityDate 2002-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0203920-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6197776-B1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396113
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394964
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398513
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54685925
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395421
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66577473
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398742
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226425987
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54675783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226415919
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4173
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398741
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411901
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396112
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54749604
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394963

Total number of triples: 48.